All five programs could potentially use the same formulation and delivery, differing only by indication, with significant patent-life extension across the family. Data and formulations generated from the influenza program can serve as the basis for developing the others commercially.
The lead. Screening and formulation work is underway for both intranasal and inhaled forms, ahead of a clinical program in influenza A/B.
